Volume 40 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
HAN Yue, SHEN Su, FU Jie, REN Qingling. Clinical Efficacy of Wandai Decoction in Preventing and Treating VVC with Spleen Deficiency-Dampness Abundance Syndrome and Its Impact on DNA Damage[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(2): 190-195. doi: 10.14148/j.issn.1672-0482.2024.0190
Citation: HAN Yue, SHEN Su, FU Jie, REN Qingling. Clinical Efficacy of Wandai Decoction in Preventing and Treating VVC with Spleen Deficiency-Dampness Abundance Syndrome and Its Impact on DNA Damage[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(2): 190-195. doi: 10.14148/j.issn.1672-0482.2024.0190

Clinical Efficacy of Wandai Decoction in Preventing and Treating VVC with Spleen Deficiency-Dampness Abundance Syndrome and Its Impact on DNA Damage

doi: 10.14148/j.issn.1672-0482.2024.0190
  • Received Date: 2023-05-08
    Available Online: 2024-02-26
  •   OBJECTIVE  To explore the clinical efficacy of Wandai Decoction in the treatment of vulvovaginal candidiasis (VVC) with spleen deficiency-dampness abundance and its effect on DNA damage.  METHODS  70 VVC patients with spleen deficiency-dampness abundance who met the inclusion criteria were randomly divided into Wandai Decoction and fluconazole groups, 35 cases each. The fluconazole group took 150 mg fluconazole orally once; the Wandai Decoction group took Wandai Decoction orally for 14 d. After treatment, changes in TCM syndrome scores of the two groups of patients were compared; the clinical cure (test of cure, TOC) rate and clinical improvement (CI) rate of the two groups of patients were evaluated; 8-hydroxydeoxyguanosine (8-OHDG) in the vaginal lavage fluid was detected by colorimetry to assess DNA damage; clinical complete remission (follow up, FU), mycological negative conversion and recurrence rate were evaluated 3 months after treatment.  RESULTS  After treatment, the TCM syndrome scores of the two groups of patients were improved to varying degrees (P < 0.05, P < 0.01); the Wandai Decoction group was superior to the fluconazole group (P < 0.05, P < 0.01); there was no significant difference in TOC, CI, mycology negative conversion between the Wandai Decoction group and the fluconazole group (P>0.05); however, the FU and recurrence rate of the Wandai Decoction group were significantly better than those of the fluconazole group (P < 0.05, P < 0.01). After treatment, the expression of 8-OHDG in the vaginal lavage fluid of the fluconazole group increased significantly (P < 0.001), while there was no significant change in the Wandai Decoction group, which was significantly lower than that of the fluconazole group (P < 0.001).  CONCLUSION  The overall clinical efficacy of Wandai Decoction is equivalent to that of fluconazole, but it is better than fluconazole in improving TCM syndromes and preventing recurrence, with the advantage of not aggravating DNA damage in vaginal cells.

     

  • loading
  • [1]
    高月倩, 白君宜, 王辰, 等. 2021年美国疾病控制和预防中心《性传播感染治疗指南》关于阴道炎症的诊治规范解读[J]. 中国实用妇科与产科杂志, 2021, 37(11): 1141-1146.

    GAO Y Q, BAI J Y, WANG C, et al. Interpretation of the diagnosis and treatment standards for vaginal inflammation in Treatment Guidelines to Sexually Transmitted Infection of US Centers for Disease Control and Prevention(2021)[J]. Chin J Pract Gynecol Obstet, 2021, 37(11): 1141-1146.
    [2]
    Vulvovaginal candidiasis (VVC)[EB/OL]. (2021-07-22)[2024-01-25]. https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm.
    [3]
    SONG N, KAN S, PANG Q, et al. A prospective study on vulvovaginal candidiasis: Multicentre molecular epidemiology of pathogenic yeasts in China[J]. J Eur Acad Dermatol Venereol, 2022, 36(4): 566-572. doi: 10.1111/jdv.17874
    [4]
    BLOSTEIN F, LEVIN-SPARENBERG E, WAGNER J, et al. Recurrent vulvovaginal candidiasis[J]. Ann Epidemiol, 2017, 27(9): 575-582. doi: 10.1016/j.annepidem.2017.08.010
    [5]
    FOXMAN B, MURAGLIA R, DIETZ J P, et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: Results from an Internet panel survey[J]. J Low Genit Tract Dis, 2013, 17(3): 340-345. doi: 10.1097/LGT.0b013e318273e8cf
    [6]
    邓霭静. 中医诊治带下病学术源流探讨及文献整理研究[D]. 广州: 广州中医药大学, 2014.

    DENG A J. The study of historical research and LiteratureCategorization for TCM diagnosis and treatment of leukorrheal diseases[D]. Guangzhou: Guangzhou University of Chinese Medicine, 2014.
    [7]
    李东垣. 脾胃论[M]. 北京: 人民卫生出版社, 2018: 6-7.

    LI D H. Treatise on the spleen and stomach[M]. Beijing: People's Medical Publishing House, 2018: 6-7.
    [8]
    傅山. 傅青主女科[M]. 北京: 人民卫生出版社, 2006: 10.

    FU S. Fu Qingzhu's treatise on gynecology[M]. Beijing: People's Medical Publishing House, 2006: 10.
    [9]
    邓高丕, 缪江霞, 周英. 带下病的中医理论与临床研究进展[J]. 广西中医药, 2001, 24(2): 59-61.

    DENG G P, MIAO J X, ZHOU Y. Progress in TCM theory and clinical research of leukorrhagia[J]. Guangxi J Tradit Chin Med, 2001, 24(2): 59-61.
    [10]
    蔡静娴. 加减完带汤巩固治疗脾虚湿盛型复发性外阴阴道假丝酵母菌病的临床疗效观察[D]. 福州: 福建中医药大学, 2019.

    CAI J X. Clinical observation on the treatment of recurrent vulvovaginal candidiasis of spleen deficiency with modified Wan Dai Decoction[D]. Fuzhou: Fujian University of Traditional Chinese Medicine, 2019.
    [11]
    梁菁, 彭艳丽. 完带汤治疗复发性外阴阴道假丝酵母菌病体会[J]. 山西中医, 2014, 30(4): 34.

    LIANG J, PENG Y L. Experience of Wandai Decoction in treating recurrent vulvovaginal candidiasis[J]. Shanxi J Tradit Chin Med, 2014, 30(4): 34.
    [12]
    PEKMEZOVIC M, HOVHANNISYAN H, GRESNIGT M S, et al. Candida pathogens induce protective mitochondria-associated type Ⅰ interferon signalling and a damage-driven response in vaginal epithelial cells[J]. Nat Microbiol, 2021, 6(5): 643-657. doi: 10.1038/s41564-021-00875-2
    [13]
    DEL FRESNO C, SOULAT D, ROTH S, et al. Interferon-β production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans[J]. Immunity, 2013, 38(6): 1176-1186. doi: 10.1016/j.immuni.2013.05.010
    [14]
    刘朝晖, 廖秦平. 外阴阴道假丝酵母菌病(VVC) 诊治规范修订稿[J]. 中国实用妇科与产科杂志, 2012, 28(6): 401-402.

    LIU Z H, LIAO Q P. Specification of diagnosis and treatment of vulvar vaginal candidiasis(VVC)-revised draft[J]. Chin J Pract Gynecol Obstet, 2012, 28(6): 401-402.
    [15]
    谈勇. 中医妇科学[M]. 4版. 北京: 中国中医药出版社, 2016: 135-143.

    TAN Y. Traditional Chinese gynecology[M]. 4th ed. Beijing: China Press of Traditional Chinese Medicine, 2016: 135-143.
    [16]
    中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002.

    Guiding principles for clinical research of new Chinese medicine: Trial implementation[M]. Beijing: China Medical Science Press, 2002.
    [17]
    中华妇产科学分会感染性疾病协作组. 外阴阴道念珠菌病诊治规范(草案)[J]. 中华妇产科杂志, 2004(6): 72-73.

    Cooperative Group of Infectious Disease, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the treatment of vulvovaginal candidiasis (draft)[J]. Chin J Obstet Gynecol, 2004(6): 72-73.
    [18]
    TSO G H W, REALES-CALDERON J A, PAVELKA N. The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future[J]. Front Immunol, 2018, 9: 897. doi: 10.3389/fimmu.2018.00897
    [19]
    FANG C J, WEI X W, WEI Y Q. Mitochondrial DNA in the regulation of innate immune responses[J]. Protein Cell, 2016, 7(1): 11-16. doi: 10.1007/s13238-015-0222-9
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Article Metrics

    Article views (83) PDF downloads(15) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return